Baillie TA - Search Results

1

MacCoss M, Baillie TA. MacCoss M, et al. Among authors: baillie ta. Science. 2004 Mar 19;303(5665):1810-3. doi: 10.1126/science.1096800. Science. 2004. PMID: 15031494

2

Approaches for minimizing metabolic activation of new drug candidates in drug discovery.

Kumar S, Mitra K, Kassahun K, Baillie TA. Kumar S, et al. Among authors: baillie ta. Handb Exp Pharmacol. 2010;(196):511-44. doi: 10.1007/978-3-642-00663-0_19. Handb Exp Pharmacol. 2010. PMID: 20020275 Review.

3

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Evans DC, et al. Among authors: baillie ta. Chem Res Toxicol. 2004 Jan;17(1):3-16. doi: 10.1021/tx034170b. Chem Res Toxicol. 2004. PMID: 14727914 Review.

4

Drug metabolites in safety testing.

Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Baillie TA, et al. Toxicol Appl Pharmacol. 2002 Aug 1;182(3):188-96. doi: 10.1006/taap.2002.9440. Toxicol Appl Pharmacol. 2002. PMID: 12229863 Review.

5

Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.

Baillie TA. Baillie TA. Chem Res Toxicol. 2008 Jan;21(1):129-37. doi: 10.1021/tx7002273. Epub 2007 Dec 4. Chem Res Toxicol. 2008. PMID: 18052111 Review.

6

Minimizing the potential for metabolic activation as an integral part of drug design.

Evans DC, Baillie TA. Evans DC, et al. Among authors: baillie ta. Curr Opin Drug Discov Devel. 2005 Jan;8(1):44-50. Curr Opin Drug Discov Devel. 2005. PMID: 15679171 Review.

7

Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.

Prueksaritanont T, Lin JH, Baillie TA. Prueksaritanont T, et al. Among authors: baillie ta. Toxicol Appl Pharmacol. 2006 Dec 1;217(2):143-52. doi: 10.1016/j.taap.2006.08.009. Epub 2006 Sep 1. Toxicol Appl Pharmacol. 2006. PMID: 17055014

8

Addressing metabolic activation as an integral component of drug design.

Doss GA, Baillie TA. Doss GA, et al. Among authors: baillie ta. Drug Metab Rev. 2006;38(4):641-9. doi: 10.1080/03602530600959466. Drug Metab Rev. 2006. PMID: 17145693 Review.

9

Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.

Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K, Baillie TA. Kumar S, et al. Among authors: baillie ta. Curr Opin Drug Discov Devel. 2008 Jan;11(1):43-52. Curr Opin Drug Discov Devel. 2008. PMID: 18175266 Review.

10

Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.

Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. Stepan AF, et al. Among authors: baillie ta. Chem Res Toxicol. 2011 Sep 19;24(9):1345-410. doi: 10.1021/tx200168d. Epub 2011 Jul 11. Chem Res Toxicol. 2011. PMID: 21702456 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

188 results

Search Page